about
Is there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive DisorderThe NKI-Rockland Sample: A Model for Accelerating the Pace of Discovery Science in PsychiatryPlasma BDNF levels vary in relation to body weight in femalesA review of the relationship between proinflammatory cytokines and major depressive disorder.Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdownIncreased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study.Soluble amyloid-β levels and late-life depressionBrain neurotoxic amyloid-beta peptides: their potential role in the pathophysiology of depression and as molecular therapeutic targets.Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.Adverse performance effects of acute lorazepam administration in elderly long-term users: pharmacokinetic and clinical predictors.A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individualsCerebrospinal fluid cortisol concentrations in healthy elderly are affected by both APOE and TOMM40 variants.Therapeutic implications of HPA axis abnormalities in Alzheimer's disease: review and update.Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variantsPathophysiology of Alzheimer's disease.Output order and variability in free recall are linked to cognitive ability and hippocampal volume in elderly individuals.Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorderAbnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study.Hippocampus and basal forebrain volumes modulate effects of anticholinergic treatment on delayed recall in healthy older adults.The Primacy Effect in Amnestic Mild Cognitive Impairment: Associations with Hippocampal Functional Connectivity.Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.State-dependent alterations in cerebrospinal fluid Aβ42 levels in cognitively intact elderly with late-life major depression.Hippocampal volume and integrity as predictors of cognitive decline in intact elderly.The recency ratio is associated with reduced CSF glutamate in late-life depression.Cognitive reserve and emotional stimuli in older individuals: level of education moderates the age-related positivity effect.Neuronal correlates of serial position performance in amnestic mild cognitive impairment.The apolipoprotein E epsilon4 allele and memory performance in HIV-1 seropositive subjects: differences at baseline but not after acute oral lorazepam challenge.Elevation in plasma Abeta42 in geriatric depression: a pilot study.Myalgia and elevation in muscle creatine phosphokinase during zimelidine treatment.Psychopharmacotherapy: from the 1950s to the 1980s.The cholinergic hypothesis of memory dysfunction in Alzheimer's disease--revisited.Lithium-induced accentuation of extrapyramidal symptoms in individuals with Alzheimer's disease.The relationship between CSF tau markers, hippocampal volume and delayed primacy performance in cognitively intact elderly individuals.Does cortical thinning in persons at increased risk for major depression also increase their risk for Alzheimer's disease?TOMM40 poly-T variants and cerebrospinal fluid amyloid beta levels in the elderly.Potential effects of the APOE epsilon2 allele and of family history of Alzheimer's disease on brain amyloid-β in normal elderly.Retrograde facilitation of verbal memory by trihexyphenidyl in healthy elderly with and without the APOE epsilon4 allele.Apolipoprotein E epsilon4 and anticholinergic cognitive toxicity.Deleterious CNS effects of the APOE epsilon4 allele in individuals with HIV-1 infection may be age-dependent.Semagacestat for treatment of Alzheimer's disease.
P50
Q26747511-B24507E3-EB0E-4561-BECA-432D0B72B6A1Q28717195-31A344E5-A60E-41D9-9E1D-F9688BF0B02FQ28727632-193513B0-63B0-4EAB-A1BC-4F7CF7AEA843Q30843122-9AC878FB-9BB6-4507-9562-BFE6A0548AC9Q33717021-463F485B-34B4-4822-97ED-F9C36AFA3B32Q33799643-0F2B4C95-10E8-4A07-A545-52731C65D568Q33933220-8E31DBE6-6322-46DD-A27D-EFA125D4F063Q34356083-ED436FEC-CC47-4CBE-8939-52981C6DAE60Q34475579-140D4358-C523-4907-ADAA-05A4035085F0Q34646697-DEB672E6-4614-4AF3-BA01-A66964B5C95CQ35132457-FF650438-F87C-4C40-9A52-561E0A1E8DCEQ35511223-63802930-3D89-4331-9CE3-F7E7927F10B7Q35607369-829F51D2-E345-4BC9-A599-C62E6B90BC5BQ35998869-BFDCB403-0155-41FF-9A7E-679F914D2B19Q36380458-7C1B686A-8F2E-4635-9A67-80D6E906621BQ36421753-1BB4AD52-5AF9-4B80-9D26-ACFB2D06962DQ36651524-9B9AB5B5-D86C-4D13-84C5-126B446CBEC7Q36915565-23929BFF-540B-4A18-863B-EDFD132AC349Q36926740-26D81E96-D972-45DF-A7A6-CE797F99838BQ37355123-13E87DE7-3C11-4764-8DD5-79216E1A65A1Q38419715-62D526E9-6125-4249-BB06-E9E4AA9A0C5DQ38832712-E7069D2D-A8EF-4A9C-9188-8EB7F77BB4A7Q38852655-180A7363-AE7B-4DDD-BE7C-D5D6A67A1D9FQ38890806-6DC93CCD-0315-47E1-AAFB-551F462B1FA4Q39232377-7D9A9C22-38E4-4137-89F1-8504F95F1D2CQ39763795-7A7C1CBA-FDD8-46F1-9958-17EC54DBFCD0Q40064649-D724DFBE-7C3C-463D-8BA1-82FABD58A55AQ40337244-6DF84413-2423-498A-957D-C01B852B8595Q40825700-F9101831-6E57-494C-BC37-4F8FDA00408DQ41470536-0B6C66FA-8EFD-4CD0-AAEB-A7354BC64326Q41470553-871AE7B7-B1A9-4393-A163-2DBBCD4EE087Q42249141-0E77074E-71D4-4472-BC01-DF29ECBBFD59Q42423876-93D7D538-D442-4040-9519-96FEB200DDABQ42576792-A14D64EA-A57F-4C87-B76A-27C5D68A2EC4Q42879000-25F7C116-0FD8-4CE1-8465-9F2172C04CACQ42968267-B86E5FBD-82DF-46B2-8337-BF688A0F9EE1Q43086780-6888E06A-01BC-493F-9A2C-0B48CF5009C4Q43178402-069F0D71-7C47-4291-873C-9DEFE345F3ECQ43251190-AF5FE60A-0798-448F-A2DB-1615F52F5E4BQ43648399-98B608F6-E560-4078-AF9D-15D058B01A6A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nunzio Pomara
@ast
Nunzio Pomara
@en
Nunzio Pomara
@es
Nunzio Pomara
@nl
Nunzio Pomara
@sl
type
label
Nunzio Pomara
@ast
Nunzio Pomara
@en
Nunzio Pomara
@es
Nunzio Pomara
@nl
Nunzio Pomara
@sl
prefLabel
Nunzio Pomara
@ast
Nunzio Pomara
@en
Nunzio Pomara
@es
Nunzio Pomara
@nl
Nunzio Pomara
@sl
P106
P21
P31
P496
0000-0003-2204-0102
P569
2000-01-01T00:00:00Z